Join to View Full Profile
450 Brookline AvenueBoston, MA 02215
Phone+1 617-632-5301
Fax+1 617-632-5786
Dr. Shaw is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2005
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1999 - 2002
Harvard Medical SchoolClass of 1999
Certifications & Licensure
MA State Medical License 2001 - 2025
American Board of Internal Medicine Medical Oncology
Clinical Trials
- AUY922 for Advanced ALK-positive NSCLC Start of enrollment: 2013 Jan 01
- Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer Start of enrollment: 2013 Jun 01
- Ponatinib in Advanced NSCLC w/ RET Translocations Start of enrollment: 2013 Sep 01
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsAlectinib combined with cobimetinib in ALK-Rearranged lung Cancer: A phase IB study.Ibiayi Dagogo-Jack, Alissa J Cooper, Bruce E Johnson, Justin F Gainor, Jessica J Lin
Lung Cancer. 2025-01-01 - Plain language summary: 5-year results from the CROWN study of lorlatinib vs crizotinib in non-small-cell lung cancer.Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip, Tony S K Mok, Ross A Soo
Future Oncology. 2024-12-01 - 55 citationsLorlatinib Versus Crizotinib in Patients With Advanced-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study.Benjamin J Solomon, Geoffrey Liu, Enriqueta Felip, Tony S K Mok, Ross A Soo
Journal of Clinical Oncology. 2024-10-10
Journal Articles
- Oxford University Press Has Registered This DOI Pre-PublicationR S Heist, Z Piotrowska, C G Azzoli, A T Shaw, I T Lennes, L V Sequist, J F Gainor, Oxford University Press
- Correlation of Extent of ALK FISH Positivity and Crizotinib Efficacy in Three Prospective Studies of ALK-Positive Patients with Non-Small Cell Lung CancerD R Camidge, A T Shaw, Annals of Oncology
Lectures
- Early circulating tumor (ct)DNA dynamics and efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC).2019 ASCO Annual Meeting - 6/1/2019
- Avelumab (anti PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101. Immunoth...2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
- Phase 3 Study of Crizotinib vs Pemetrexed or Docetaxel Chemotherapy in Patients with Advanced ALK+ NSCLC2012 Congress, Vienna, Austria
- Join now to see all
Other
- Anaplastic lymphoma kinase (ALK) fusion oncogene positive non-small cell lung cancerShaw AT, Solomon B
http://www.uptodate.com/contents/anaplastic-lymphoma-kinase-alk-fusion-oncogene-positive-non-small-c
UpToDate, Wolters Kluwer Health - 2013-04-09
Press Mentions
Daily Takeaways from the AACR Annual Meeting 2025: Monday, April 28April 28th, 2025- Dana-Farber Experts Present Innovative Cancer Studies at the 2025 AACR Annual MeetingApril 26th, 2025
- Dana-Farber Research Highlights Head and Neck, Breast, Lung, and Survivorship Studies at AACR Annual Meeting 2025April 25th, 2025
- Join now to see all
Grant Support
- Identification Of Resistance Mechanisms To Anaplastic Lymphoma Kinase InhibitorsNational Cancer Institute2012
- RAS Signaling In Development And CancerNational Cancer Institute2005–2009
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
